SCHEMBL5453533

SCHEMBL5453533

NC(=O)c1c(NC(=O)c2c[nH]cn2)sc2c1CCCC2

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.67
RAB9A P51151 7/20 0.65
NPC1 O15118 6/20 0.65
ALDH1A1 P00352 5/20 0.65
MAPT P10636 4/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
HPGD P15428 2/20 0.59
POLB P06746 1/20 0.58
CFTR P13569 2/20 0.57
KDM4E B2RXH2 2/20 0.57
GAA P10253 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453576 0.80 FLT3 (1.00) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL5455700 0.79 RAB9A (1.00) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL8290663 0.78 FLT3 (1.00) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL5467221 0.78 FLT3 (0.70) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL5453550 0.78 FLT3 (0.67) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL22789508 0.78 FLT3 (0.61) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL8289853 0.77 FLT3 (0.97) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL5458447 0.76 ALDH1A1 (0.68) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL5456042 0.76 FLT3 (0.60) FLT3RAB9ANPC1ALDH1A1MAPT
SCHEMBL8289437 0.76 FLT3 (0.95) FLT3RAB9ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885RAB9A 948/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.